A Randomised, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Inhaled Doses of VR942 in Healthy Subjects and Repeated Doses in Mild Asthmatics

Trial Profile

A Randomised, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Inhaled Doses of VR942 in Healthy Subjects and Repeated Doses in Mild Asthmatics

Completed
Phase of Trial: Phase I

Latest Information Update: 24 May 2017

At a glance

  • Drugs VR 942 (Primary)
  • Indications Asthma
  • Focus Adverse reactions; First in man
  • Sponsors Vectura
  • Most Recent Events

    • 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society
    • 22 Nov 2016 According to a Vectura Group plc media release, the company plans to present results from this trial at ehe American Thoracic Society in May 2017.
    • 03 Jun 2016 According to a Vectura media release, detailed study outcomes will be presented at a future scientific conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top